Twitter

Making a positive difference for patients is what fuels our mission.

To learn more about our patients battling central nervous system disorders and rare diseases, visit: http://www.marinuspharma.com/for-patients-families/patient-stories

The path to herd immunity is not by getting the herd sick
https://www.nytimes.com/interactive/2020/05/28/upshot/coronavirus-herd-immunity.html?smid=tw-share @UpshotNYT by @PopovichN and @sangerkatz ★ @nytgraphics

Buenos días a todas y todos!
Es un placer anunciaros que nuestra asociación ya puede ser beneficiaria de las recaudaciones de fondos de Facebook. Así que cuando llegue vuestro cumpleaños o si tenéis pensado en hacer algún tipo de recaudación benéfica, somos una opción
¡Gracias!

Dopo il verbo “amare” il verbo “aiutare” è il più bello del mondo. La nostra missione è quella di trovare una cura per la sindrome CDKL5. Destina il tuo 5 x 1000 alla nostra associazione e aiutaci in questa impresa - CF 92049350157 GRAZIE!!#insiemeversolacura #donare #solidarietà

10 interesantes temas locutados, por ponentes de referencia. Hemos intentado que sean interesantes y amenas. Animate a escucharlas
Pildoras de conocimiento en:

http://www.neurotalks.es/

Karen Utley shares her motivation for joining fellow parents to found @CDKL5USA: “It gave me a sense of control in an out of control situation. I can make this world better for kids like my daughter.” For resources and community support, visit http://www.cdkl5.com

¿Por qué parece menos importante el diagnóstico y tratamiento precoz en #Epilepsia?

Quizás se debe a la alta proporción de “idiopáticas”. Pero la irrupción de causas inmunológicas y genéticas, o un mayor número de operables ha cambiado el panorama👇

https://neuronews.prosaludmental.es/que-paso-con-el-time-is-brain-en-epilepsia/

The gnomAD package is officially out! We look at those genes where we see loss-of-function variants, but also those where we don't see any, and learn a lot about genes along the way: https://www.nature.com/articles/s41586-020-2308-7

New review by Graus, Saiz and Dalmau on GAD antibodies in neurological disorders including stiff-person syndrome, cerebellar ataxia and epilepsy

https://www.nature.com/articles/s41582-020-0359-x

Our Chairman and CEO John F. Crowley has co-authored an article for @STATNews: “Beating COVID-19 Will Change How New Therapies are Developed”, exploring how the pandemic will potentially transform the future of drug development.
https://www.statnews.com/2020/05/27/beating-covid-19-will-change-how-new-therapies-are-developed/

Carica altri...